Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. - Wikidata - awgldk - TriplyDB

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

http://www.wikidata.org/entity/Q36032750

about

Management of HCV-Associated Liver Cirrhosis.Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective Recent Advances in Antiviral Therapy for Chronic Hepatitis C KASL clinical practice guidelines: management of hepatitis C Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Interferon-free combination therapies for the treatment of hepatitis C: current insights Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Hepatitis C treatment: where are we now?New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current Therapies Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment SASLT guidelines: Update in treatment of Hepatitis C virus infection.The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Why I do not treat patients for mild disease.In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C.Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free Regimen Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.Hepatitis C virus genotype 4: Genotype 1's little brother.Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.Urgency to treat patients with chronic hepatitis C in Asia.Hepatitis C virus management: potential impact of nanotechnology.Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.

P2860

Q26740320-8D026E3C-8D28-4E49-9323-40A628D4C85A Q26746910-2C377DFE-4FC9-4C65-8A47-EADBDDF544C2 Q26750476-AD03B1C4-8118-49A6-9EC3-96172AEB7C59 Q26752471-10C589CD-41F5-40B3-A030-8F703979948A Q27468696-811B4557-34F3-48C7-9ED2-38107F9C0B5B Q28067411-AD11BB0C-6991-4D6D-86C2-76CC2E5D0EAD Q28080160-07594865-A08D-4756-A32E-F0D44DF225B1 Q28080225-B2E21ABB-1C2A-4B80-B287-D6B351F87E30 Q28087400-C5D8F2E8-13EE-42B2-8988-9F352E947CE1 Q30355190-CC0DFA88-D012-435A-9CE0-5949A47EE05A Q30378509-C478313A-57C3-45CF-9A2C-41466AAC375F Q33560181-4105467C-C1E8-4C1D-86CD-F7B8C8EFE64F Q33585021-5ADBAF20-A9A8-4014-BA5F-035D29854E2E Q33698956-3D787EC4-A051-4984-A9B6-F6BDCA22268F Q36166222-CCDED999-8202-4833-B05C-A59ED1AE77BE Q36261373-9FEF99F1-D061-4188-8BFA-5725507D14DD Q36519126-921D1789-708E-4A82-AB5F-8576A45BB7FC Q36870118-2AFB00F2-7D15-4233-A4C8-C748BD916C8D Q36981033-2DF494CE-1814-4C99-A7D3-F05FACFAF78F Q37040485-E08B3A13-37D2-45B7-BFAF-9698FA30D600 Q37100669-307683D4-872B-41FE-825D-A8D529F6FFE1 Q37216507-D6AFCDF4-3FC6-4EB7-8CED-CB37DD667B00 Q37555313-AC9CCDE7-65A5-4914-9537-817C05808D54 Q38602682-8C8E8A0A-467A-4C3D-8E64-564470465744 Q38685566-CEB62D82-44A3-4DC0-B708-D490752989F4 Q38740523-58338B35-30A0-4A69-98E3-C4A505ECF657 Q38742966-A6A3FCB0-8C18-4B92-A26F-3342B6EA30F9 Q38863925-2B4AE88F-5EBE-433F-8452-2596A02C8110 Q38880996-74374B32-C082-4EDF-A0D0-FC0D4FB220E8 Q38893128-A69EFEB7-3730-4493-9F13-5982A38F5D96 Q38893244-BD431DC0-847E-4384-83AB-0C361F0A5A62 Q38927205-F3144D30-5FF8-4481-925D-163F1899930C Q38959188-1C6821CB-219B-4DCE-BA71-F14C7EDD4728 Q39025320-551B05C3-8144-4FD9-A7AC-7B168AFE12D6 Q39032538-4BFBB329-2CF4-44C6-84EA-0703FCD3B091 Q39049155-8E19AD91-3C4D-40A4-A16F-EB2743DEC9E7 Q39278958-891A768B-F76B-45FE-8452-A000AC2E45D6 Q40211449-8863E322-52BF-4EC0-8EFE-33B131D71D20 Q40292229-2BA39750-9DD4-4B93-9378-CDFB786D872C Q40466129-FCB42110-E78C-4FB1-B7BB-7BA8EE4C4F9B

P2860

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

http://www.wikidata.org/entity/Q36032750

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.

@ast

Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.

@en

type

label

Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.

@ast

Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.

@en

prefLabel

Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.

@ast

Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.

@en

P1433

Q36032750-02ABD88F-BA08-42F4-97F3-9D72D91BCFB6

P1476

Q36032750-AEB1C711-3135-4888-8EA6-6A2285C82E17

P2093

Q36032750-11723E42-F977-49A0-93AD-20EB82076FFC

Q36032750-1341FC9D-F59C-4D85-8B2F-4775EA342A09

Q36032750-314F37C9-F6FE-4E11-ABC6-54C2CC83C023

Q36032750-41D650DB-E17F-4EFB-85F3-32870123E3C7

Q36032750-43A4E3D4-5322-4E72-B682-393FFBEBC13C

Q36032750-4655076B-EE00-43F0-8039-722587D23FD1

Q36032750-598E09A1-AFA5-4039-A38B-40954165F162

Q36032750-6173A6D4-82A7-4916-B85E-AF492BADFB04

Q36032750-63FCFD4F-4C27-4F9F-B389-A8D178A0C8A4

Q36032750-68F3CDBF-5F0F-4978-A7CF-F4989E5A8DD0

P2860

Q36032750-06ED1F01-AD07-4E98-A0D3-B39B95B092F3

Q36032750-08E2ACE0-017B-4911-AD0C-19639EF4B894

Q36032750-1C69EC46-D35F-41E0-9B3A-AF2374EFEE98

Q36032750-21E698E9-9AE1-44A6-BBA8-6864B43E5592

Q36032750-27870617-8CD0-4608-AC04-B7AE9297F95F

Q36032750-50AC4012-B770-4886-B956-AFDD5B44C3ED

Q36032750-56CE6E23-EA91-4D91-A01A-0E48BFAC7F30

Q36032750-6525AC34-8A85-440C-B407-DD724ED6A839

Q36032750-6B2BDEE5-034F-45C7-B89B-08FA2167A68E

Q36032750-7A3458D2-0508-4557-B312-507CD795B4F0

P304

Q36032750-6DB55979-E60F-42A0-BCB7-F9786AE60AE8

P31

Q36032750-2625DE37-E75D-4842-846E-7D2AEB92D56C

P356

Q36032750-E8FDCD8A-4387-4D30-8AA1-AF5F235CA379

P433

Q36032750-E25518E0-A8ED-4FA9-9F7C-5412B3DF2B83

P478

Q36032750-97D93908-E321-4C5B-B756-A87EE6EDDF90

P50

Q36032750-9B6C035C-CFA9-49F8-80F0-4AA6EC5ABAD3

P577

Q36032750-8B76024A-EDE9-43E3-888D-5D9557C31FB5

P698

Q36032750-1A34CBDF-849C-492F-B29D-4F24A4042971

P921

Q36032750-EBF18199-71D1-4D15-949F-F813733DA7AD

P932

Q36032750-57B9FED1-1EE1-468F-97AE-92CE9559A257

P356

S1473-3099(15)00157-7

P1433

The Lancet Infectious Diseases

P1476

Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.

@en

P2093

Amy Nelson

http://www.w3.org/2001/XMLSchema#string

Anita Kohli

http://www.w3.org/2001/XMLSchema#string

Anu Osinusi

http://www.w3.org/2001/XMLSchema#string

Brian Lam

http://www.w3.org/2001/XMLSchema#string

Chloe Gross

http://www.w3.org/2001/XMLSchema#string

Colleen Kotb

http://www.w3.org/2001/XMLSchema#string

Gebeyehu Teferi

http://www.w3.org/2001/XMLSchema#string

Henry Masur

http://www.w3.org/2001/XMLSchema#string

Kate Sugarman

http://www.w3.org/2001/XMLSchema#string

Michael A Polis

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology and genotype distribution of the hepatitis C virus infection

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

Sofosbuvir for previously untreated chronic hepatitis C infection

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Global distribution and prevalence of hepatitis C virus genotypes.

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.

P304

1049-1054

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1473-3099(15)00157-7

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26187031

http://www.w3.org/2001/XMLSchema#string

P921

P932

4561573

http://www.w3.org/2001/XMLSchema#string